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RNF208, an estrogen-inducible E3 ligase, targets
soluble Vimentin to suppress metastasis in triple-
negative breast cancers
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The development of triple-negative breast cancer (TNBC) negatively impacts both quality of
life and survival in a high percentage of patients. Here, we show that RING finger protein 208
(RNF208) decreases the stability of soluble Vimentin protein through a polyubiquitin-
mediated proteasomal degradation pathway, thereby suppressing metastasis of TNBC cells.
RNF208 was significantly lower in TNBC than the luminal type, and low expression of
RNF208 was strongly associated with poor clinical outcomes. Furthermore, RNF208 was
induced by 17β-estradiol (E2) treatment in an estrogen receptor alpha (ΕRα)-dependent
manner. Overexpression of RNF208 suppresses tumor formation and lung metastasis of
TNBC cells. Mechanistically, RNF208 specifically polyubiquitinated the Lys97 residue within
the head domain of Vimentin through interaction with the Ser39 residue of phosphorylated
Vimentin, which exists as a soluble form, eventually facilitating proteasomal degradation of
Vimentin. Collectively, our findings define RNF208 as a negative regulator of soluble
Vimentin and a prognostic biomarker for TNBC cells.
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Breast cancer is one of the most common cancers worldwideamong women1. Among the molecular subtypes of breastcancer, ERα-positive breast tumors are a well-differentiated
phenotype and are correlated with a better prognosis than ERα-
negative breast tumors, which are extremely aggressive subtypes
associated with a poor prognosis2,3. Although ERα-positive breast
tumors initially respond to hormonal manipulation, such as
tamoxifen, which is an antiestrogen agent, patients with triple-
negative breast cancer (TNBC) or ERα-negative breast tumors do
not benefit from antihormonal therapy or traditional che-
motherapy4–6. In this regard, different prognostic and therapeutic
applications based on molecular features are necessary for breast
cancer patients.
Dysregulation of ERα is often associated with advanced breast
cancers by altering the ERα-dependent genes that are involved in
cell proliferation and metastasis. The loss of ESR1 expression in
TNBC is a result of the hypermethylation of specific CpG islands
within the ESR1 promoter through regulation of DNA methyl-
transferase (DNMT)7,8. Furthermore, ERα re-expression by 5-
aza-dC, a DNMT inhibitor, was shown to inhibit tumor growth of
TNBC cells in vitro and in vivo, indicating that its expression can
be modulated by epigenetic mechanisms and restore the sensi-
tivity of TNBC to endocrine therapy9. Although the function of
ERα has been extensively studied in breast cancer, how the loss of
ERα contributes to tumorigenesis and metastasis in TNBC is
unclear.
Vimentin, an intermediate filament protein, is highly expressed
in aggressive epithelial cancers, including breast cancer, prostate
cancer, gastric cancer, malignant melanoma, and lung cancer,
where its expression level is associated with increased risks of
metastasis10. Aberrant expression of Vimentin is restricted to
TNBC cells among the breast cancer cells and is involved in a
mesenchymal phenotype, aggravating the invasive potential of
breast cancer cells. Vimentin regulates cell adhesion and motility
through its phosphorylation (soluble form) and depho-
sphorylation (insoluble form)11–13. Furthermore, posttransla-
tional modifications (PTMs), such as O-linked glycosylation,
ubiquitination, sumoylation, and acetylation, are known to reg-
ulate the function of Vimentin14. Recently, the E3 ubiquitin ligase
TRIM56 was revealed to be a negative regulator of Vimentin by
inducing polyubiquitination-mediated proteasomal degradation,
resulting in a decrease of cell migration and invasion15. Although
Vimentin function is widely studied in cancer metastasis, the
molecular mechanisms by which the suppression of Vimentin
ameliorates metastasis in aggressive cancer cells remain to be
identified.
In this study, we show RNF208, an estrogen-inducible E3 ligase
protein, specifically induces degradation of soluble Vimentin
through K27-linked polyubiquitination of phosphorylated
Vimentin at the Ser39 residue, thereby suppressing the metastasis
of aggressive TNBC cells.
Results
RNF208 is significantly underexpressed in aggressive TNBC.
To identify biomarkers associated with breast cancer progression,
we initially performed RNA sequencing in several breast cancer
cell lines, classified as either the luminal subtypes (MCF-7, T47D,
ZR-75B) or TNBC (MDA-MB-231, Hs578T). Based on the
transcriptome analysis, we found that RNF208 was significantly
underexpressed in TNBC cells compared to luminal breast cancer
cells (GSE100878) (Fig. 1a). This finding was supported by RT-
PCR and immunoblot analysis (Fig. 1b). Moreover, gene
expression analysis of a public microarray dataset (GSE41313)
with 52 breast cancer cell lines showed significantly lower
expression of RNF208 in TNBC cells compared to luminal cells
(Fig. 1c). We further analyzed RNF208 expression in different
breast cancer subtypes using microarray and RNA sequencing
datasets of breast cancer patients obtained from Genomic Data
Commons (GDC) datasets and public microarray datasets
(GSE2034). Consistently, RNF208 expression was significantly
decreased in patients with TNBC compared to luminal A, luminal
B, and HER2-enriched patients (Fig. 1d−f). We next examined
the RNF208 protein and mRNA levels in human primary breast
tumor specimens by immunohistochemistry staining and quan-
titative RT-PCR. Notably, the expression of RNF208 was
remarkably lower in the tumor compartments of patients with
TNBC compared to those with the luminal subtypes (Fig. 1g), and
RNF208 mRNA was significantly decreased in TNBC tissues
(Fig. 1h). To address the functional significance of the association
of RNF208 expression with clinical outcomes in breast cancers,
we performed public meta-analyses using Kaplan−Meier Plotter
software16. Interestingly, patients with low RNF208 expression
exhibited significantly shorter relapse-free survival times than
those with high expression (Fig. 1i). Moreover, the low expression
of RNF208 was strongly correlated with poor relapse-free survival,
regardless of breast cancer subtypes (Supplementary Fig. 1).
Taken together, these results suggest that RNF208 is closely
associated with aggressive breast cancer and may serve as a
predictive factor for the risk of developing relapse disease in
breast cancer patients.
ERα regulates RNF208 expression. Because RNF208 expression
was increased in luminal breast cancer subtypes, which are ERα-
positive, we investigated the relationship between RNF208 and
ERα expression using public microarray datasets (GSE2034;
GSE5460). The expression of RNF208 was positively correlated
with the ERα status in breast cancers (Fig. 2a). Next, we tested
whether RNF208 may be a bona fide estrogen-responsive target
gene. MCF-7 and T47D cells were cultured in phenol-free media
with charcoal stripped serum to remove residual exogenous
estrogens and estrogen-like compounds. Interestingly, RNF208
expression was markedly induced by E2 treatment, similar to
other ERα-responsive genes, such as FOXOM1 and GREB1
(Fig. 2b), and siRNA-induced ESR1 knockdown attenuated the
E2-induced expression level of RNF208 in T47D cells (Fig. 2c),
indicating that RNF208 expression may depend on ERα expres-
sion in luminal breast cancer cells. To determine whether the
expression of RNF208 induced by E2 is associated with direct
transcriptional activation of the RNF208 promoter, we generated
deletion constructs of the RNF208 promoter, which contains
estrogen-responsive elements (EREs), inserted upstream of a
pGL3 luciferase reporter gene (Fig. 2d; Supplementary Fig. 2a).
Notably, E2 treatment increased the luciferase activity of the
RNF208 promoter fragment up to −1154 bp, whereas deletion of
position −1121 bp or −724 bp was not responsive to E2 treat-
ment in T47D and MCF-7 (Fig. 2e; Supplementary Fig. 3a). To
determine whether E2-induced activation of the RNF208 pro-
moter increased the direct binding of ERα to the RNF208 gene
locus, we conducted chromatin immunoprecipitation (ChIP)
using the anti-ERα antibody in T47D cells. E2 treatment dra-
matically increased the interaction of ERα within the −1131 bp to
−1124 bp promoter region, which contains one ERE site, indi-
cating that endogenous ERα is recruited to the RNF208 promoter
(Fig. 2f). To further characterize which ERE site located in the
−1131 bp to −1124 bp region is responsible for E2-induced
activation of the RNF208 promoter, we generated an ERE mutant
construct (mtR4) carrying two substitutions (GACC to GAAA).
The luciferase activity of the full-length RNF208 promoter was
increased by E2 treatment in T47D cells and MCF-7, whereas the
ERE mutation markedly abolished RNF208 promoter activation
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(Fig. 2g; Supplementary Fig. 3b). Furthermore, deletion of −1131/
−1124 bp region of RNF208 promoter markedly attenuated the
E2-induced RNF208 expression in MCF-7 cells (Fig. 2h). As
RNF208 is poorly expressed in TNBC cells, we next investigated
whether downregulation of RNF208 is a result of aberrant DNA
methylation within its promoter in TNBC cells using a public
genome database (GSE68379). The methylation levels of the
RNF208 promoter were not significant in TNBC cells, indicating
that methylation is not involved in RNF208 silencing (Supple-
mentary Fig. 2). Considering that ESR1 expression is suppressed
by epigenetic mechanisms, such as DNA methylation, in TNBC
cells, we further examined whether low expression of RNF208 in
TNBC cells might be due to silencing of ESR1 expression by DNA
methylation. Interestingly, 5-aza-dC treatment resulted in an
increase in the expression levels of ERα and RNF208 in TNBC
cells (MDA-MB-231, Hs578T) (Fig. 2i, Supplementary Fig. 3c).
More strikingly, ERα knockdown by siRNA attenuated the 5-aza-
dC-induced increase of RNF208 in TNBC cells, implying that
ERα expression is required for the induction of RNF208 (Fig. 2j).
Taken together, our results suggest that RNF208 is a direct
estrogen-responsive target gene that is dependent on ERα.
RNF208 overexpression reduces the tumor growth and lung
metastasis. Our findings led us to verify the physiological func-
tion of RNF208 in breast cancer progression. We first investigated
whether the expression level of RNF208 affects tumorigenesis
in vitro and in vivo. RNF208 overexpression markedly reduced
the proliferation of TNBC cells (Fig. 3a). To further test the effect
of RNF208 on the tumorigenic capacity of TNBC cells in vivo, we
injected RNF208-tolu TNBC cells subcutaneously into the flanks
of immunodeficient mice. Overexpression of RNF208 dramati-
cally attenuated the tumor volume of TNBC cells (Fig. 3b).
Furthermore, expression of Ki-67, a marker of cell proliferation,
RNF208
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Fig. 1 RNF208 is significantly underexpressed in highly metastatic breast cancer cells. a Volcano plot of RNF208 expression in luminal subtype (MCF-7,
T47D, and ZR-75B) and TNBC (MDA-MB-231 and Hs578T) cells using RNA sequencing (GSE100878). b RT-PCR and immunoblot analysis of RNF208
expression in breast cancer cells. c Scatter plots of RNF208 expression in 52 breast cancer cells from public microarray datasets (GSE41313) (Luminal N=
29 and TNBC N= 23 cells). d, e Heat map and box plots showing the expression levels of RNF208, ESR1, and ERBB2 across the breast cancer subtypes using
Genomic Data Commons (GDC). (Luminal A N= 335, Luminal B N= 88, HER2 N= 23 and TNBC N= 55 patients). f Comparison of RNF208 expression in
breast cancer subtypes using published microarray datasets (GSE2034) (Luminal N= 154 and TNBC N= 55 patients). g Representative
immunohistochemical (IHC) staining of RNF208 protein expression classified in luminal and basal breast cancer patient tissues. Original magnification
×100. Scale bar, 50 μm. h Real-time quantitative RT-PCR of RNF208 expression in luminal subtype tissues (N= 6) and TNBC tissues (N= 6); 18S rRNA
was used as an internal control. i Kaplan−Meier analysis showing relapse-free survival depending on RNF208 expression levels from public meta-analysis
data (N= 3951). P values were calculated using a log-rank test. All P values were calculated by unpaired two-tailed Student’s t tests (c, e, f, and h). These
data represent the mean ± S.D. Source data for (c, f, h) is available in Source Data file. Unprocessed original scans of blots and gels in (b) are shown in
Supplementary Fig. 13.
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was decreased (Fig. 3c; Supplementary Fig. 4a), whereas active
caspase-3, a marker of cell death, was increased in RNF208-
overexpressing primary tumor tissues compared with control
tissues (Fig. 3d; Supplementary Fig. 4b).
Because tumorigenic potential is closely associated with
enhanced invasiveness for metastasis of tumor cells, we next
examined whether RNF208 affects cell migration and invasive-
ness using Transwell migration and Matrigel invasion assays.
Overexpression of RNF208 significantly decreased cell migration
and invasion in Hs578T and MDA-MB-231 cells (Fig. 3e, f). We
further observed that RNF208-overexpressing MDA-MB-231
cells showed a significant reduction in lung metastasis as well
as metastatic pulmonary nodules in immunodeficient mice
(Fig. 3g, h). We then investigated whether the loss of RNF208
increases the aggressive potential in the luminal subtype of breast
cancer cells. Unexpectedly, neither knockdown nor knockout of
RNF208 did change the expression of epithelial to mesenchymal
transition (EMT) markers, such as E-cadherin and Vimentin, or
the cell migration ability of both control and RNF208-deficient
T47D cells (Supplementary Fig. 5), suggesting that loss of
RNF208 may not be sufficient to induce aggressive phenotypes
and cancer progression in luminal breast cancer subtypes. Taken
together, these results strongly suggest that RNF208 may act as a
tumor suppressor in the cancer progression of TNBC cells.
RNF208 overexpression decreases the stability of Vimentin
protein. To assess the molecular mechanism underlying RNF208
function in breast cancer progression, we performed a mass
spectrometry-based formaldehyde crosslinking assay in RNF208-
overexpressing MDA-MB-231 cells. Through mass spectrometry
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analysis, Vimentin was identified as a potential binding protein of
RNF208 (Fig. 4a). Because Vimentin is associated with the
mesenchymal phenotype of aggressive cancer cells in metastatic
cancer progression, we first investigated whether RNF208 reg-
ulates the expression of EMT markers in Hs578T and MDA-MB-
231 cells. Interestingly, RNF208 overexpression strongly
decreased the expression level of Vimentin protein without
affecting its mRNA or E-cadherin expression (Fig. 4b, c). To
determine whether the reduced expression level of Vimentin in
RNF208-overexpressing cells is an account of its attenuated
protein stability, we measured the half-life of Vimentin protein
after treatment with cycloheximide, a protein synthesis inhibitor.
RNF208-ovexpressing MDA-MB-231 cells showed a faster rate of
Vimentin degradation compared to control cells (Fig. 4d).
Moreover, decreased Vimentin stability under RNF208 over-
expression was rescued by treatment with the proteasome
inhibitor MG132 but not by autophagy inhibitors such as bafi-
lomycin A1 (BAF), chloroquine (CQ), and 3-methyladenine (3-
MA) (Supplementary Fig. 6b). Consistent with this observation,
decreased stability of Vimentin in cells with ectopic expression of
RNF208 was also markedly restored by MG132 treatment
(Fig. 4e).
Since Vimentin is identified as a binding partner of RNF208, we
next tested the interaction between RNF208 and Vimentin by
coimmunoprecipitation in 293T and Hs578T cells. As expected,
immunoprecipitation assays showed either exogenous or endogen-
ous interactions between these two proteins (Fig. 4f; Supplementary
Fig. 6c). Considering the ubiquitin transfer activity of RNF208 E3
ligase, we next investigated whether RNF208 mediates the
ubiquitination of Vimentin. Notably, ectopic overexpression of
RNF208 induced the polyubiquitination of Vimentin (Fig. 4g). To
pinpoint whether RNF208-polyubiquitinated Vimentin is linked to
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metastasis from 6 to 8 weeks, derived from lateral tail-vein injection of control and RNF208-overexpressing MDA-MB-231-Luc. h Representative whole
lung image stained with India ink showing metastatic nodules (top) and scatter plot showing the number of lung metastatic nodules (bottom). All P values
were calculated by unpaired two-tailed Student’s t tests (a, b, and h). The data represent the mean ± SD. Source data for (a, b, e, f, h) are available in
Source Data file. Unprocessed original scans of blots and gels in (d) is shown in Supplementary Fig. 13.
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any type of polyubiquitin chains, 293T cells were transiently
transfected with Flag-Vimentin together with HA-Ubiquitin (wild-
type, K27, K29K, K48, and K63) in the presence or absence of Myc-
RNF208 upon MG132 treatment. Interestingly, RNF208 specifically
promoted a robust polyubiquitination of Vimentin by K27-only
ubiquitin (HA-K27 Ub) in the same pattern as wild-type HA-Ub,
not by any other chain types (Fig. 4h). Further experiments using
the K27R ubiquitin mutant, in which the lysine 27 residue of
ubiquitin was mutated to arginine (HA-K27R Ub), revealed that
RNF208-induced polyubiquitination of Vimentin was not detected
in the presence of K27R, indicating that the polyubiquitination of
Vimentin by RNF208 may be dependent on K27 ubiquitin-linked
chain formation (Fig. 4i). An immunoprecipitation assay showed
that RNF208 overexpression induced an endogenous K27-linked
polyubiquitination of Vimentin in MDA-MB-231 cells (Supple-
mentary Fig. 6c). Taken together, our results suggest that RNF208
decreases the stability of Vimentin through K27 ubiquitin-linked
polyubiquitination, positioning RNF208 as a novel negative
regulator of Vimentin in TNBC cells.
RNF208 expression is inversely correlated with Vimentin
expression. We next prompted an investigation of the relevance
between RNF208 and Vimentin expression in patients with breast
cancer. To this end, we used breast cancer TMAs obtained from
the Seoul National University College of Medicine in South
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Korea. Notably, RNF208 and Vimentin were inversely expressed
in patients with luminal subtype cancer and TNBC tissues
(Fig. 5a, b). To further support this observation, we examined
matched tumor samples in patients with breast cancer. Indeed, a
significant inverse relationship between RNF208 and Vimentin
expression was observed in matched tumor tissues of patients
with breast cancer (Fig. 5c). Furthermore, expression of Vimentin
was decreased in RNF208-ovexexpressing primary tumor tissues
compared with control tissues in xenograft mouse experiment
(Fig. 5d). Taken together, these results suggest that RNF208
expression is closely associated with Vimentin-mediated aggres-
sive cancer progression of breast cancer cells.
Activity of RNF208 is required for the degradation of
Vimentin. Considering that RNF208 contains a RING domain,
which possesses E3 ligase activity for ubiquitination, we assumed
that the RING domain of RNF208 might interact with Vimentin
to facilitate polyubiquitination. Indeed, an immunoprecipitation
assay showed that Vimentin specifically bound to the RING
domain of RNF208, which harbors the E3 ligase activity, but not
to the N-terminal and C-terminal regions (Supplementary
Fig. 7a). In parallel with this result, given that the cysteine-rich
motifs are known as the active site of E3 ligase activity, we also
examined whether activity of RNF208 is responsible for the
polyubiquitination of Vimentin. To this end, we generated
RNF208 mutants (C143A, C167A, and C186A) in which putative
cysteine-rich motifs in the RING domain of RNF208, which are
highly conserved in different species (Supplementary Fig. 7b),
were substituted with alanine. Importantly, the inactive mutants
of RNF208 did not bind to Vimentin (Fig. 6a), and the C143A/
C167A/C186A (3MT) mutant of RNF208 was unable to promote
polyubiquitination of Vimentin (Fig. 6b). In addition, immuno-
blot analysis showed that ectopic expression of the Myc-RNF208
(3MT) mutant could not induce Vimentin degradation (Fig. 6c).
Therefore, C143, C167, and C186 sites within the RING domain
of RNF208 are crucial for the polyubiquitination-mediated
degradation of Vimentin. Moreover, we found that
RNF208 specifically bound to the head domain of Vimentin but
not to the rod and tail domains (Supplementary Fig. 7c). Based on
the fact that ubiquitination occurs at lysine residues of target
proteins, we identified one lysine residue in the head domain of
Vimentin. To examine whether this residue is critical for
RNF208-mediated polyubiquitination of Vimentin, we generated
a Vimentin mutant (K97A) by replacing Lys97, which is evolu-
tionarily conserved in different species, with alanine (Supple-
mentary Fig. 7d). While wild-type Vimentin was subjected to
polyubiquitination by RNF208, the Vimentin (K97A) mutant did
not undergo polyubiquitination (Fig. 6d). Additionally, cyclo-
heximide treatment revealed that the stability of the Vimentin
(K97A) mutant was not influenced in the presence of RNF208
(Fig. 6e, f). Thus, the Lys97 residue of Vimentin is a major target
of RNF208-induced polyubiquitination of Vimentin for regulat-
ing its stability.
Next, we investigated whether the activity of RNF208 E3 ligase
directly influences the metastatic potential of TNBC cells in vivo
using wild-type and the 3MT mutant RNF208-overexpressing
MDA-MB-231 cells. Interestingly, RNF208 (3MT) mutant-
overexpressing MDA-MB-231 cells resulted in a significant
increase of cell proliferation and migration as well as metastatic
pulmonary nodules in immunodeficient mice, similar to those of
control cells (Fig. 6g; Supplementary Fig. 8). In accordance with
this observation, immunohistochemistry staining of lung metas-
tasis tissues showed that RNF208 overexpression decreased the
expression levels of Vimentin in the tissue sections, whereas the
RNF208 (3MT) mutant did not affect its expression levels
(Fig. 6h). We further examined whether expression of the
nondegradable K97A mutant version of Vimentin in RNF208
expression cells can rescue the metastasis phenotypes. We used
siRNA targeting VIM to delete the endogenous Vimentin level
and overexpressed wild-type Vimentin or Vimentin (K97A)
mutant in control and RNF208-overexpressing MDA-MB-231
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cells. Interestingly, RNF208 overexpression markedly decreased
cell migration in control cells as well as wild-type Vimentin-
overexpressing cells, whereas RNF208 overexpression-induced
reduction in cell migration was rescued in Vimentin (K97A)
mutant-overexpressing cells (Supplementary Fig. 9a). Consistent
with this observation, an increase in metastatic pulmonary
nodules was observed in mice injected with RNF208/Vimentin
(K97A) mutant-overexpressing cells compared with RNF208 or
RNF208/wild-type Vimentin-overexpressing cells, indicating that
RNF208 decreases lung metastasis by targeting the Lys97 residue
of Vimentin (Supplementary Fig. 9b). Collectively, these results
suggest that activity of RNF208 E3 ligase is required for the
polyubiquitination-mediated degradation of Vimentin through
interaction with the head domain, eventually attenuating the
metastatic capacity of TNBC cells.
RNF208 targets the phosphorylation of Vimentin at the Ser39
residue. Studies have reported that several serine residues within
the N-terminal head domain of Vimentin are phosphorylated by
various kinases, and phosphorylated Vimentin in turn is dis-
assembled and present in the soluble fraction in the cytoplasm,
eventually promoting cell migration and invasiveness13,17. Based
on the fact that phosphorylated Vimentin as a soluble form is
associated with metastasis, we hypothesized that RNF208 may
induce the degradation of soluble Vimentin by recognizing
phosphorylated Vimentin. To assess our hypothesis, we initially
confirmed the expression level of Vimentin in the soluble and
insoluble fractions in RNF208-overexpressing MDA-MB-231 cells.
Interestingly, RNF208 was predominantly located in the soluble
fraction, and its overexpression led to a significant reduction of
Vimentin in the soluble fraction compared with the insoluble
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per group). Scatter plot showing the number of lung metastatic nodules (right). The P value was calculated by unpaired two-tailed Student’s t tests. The
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fraction (Fig. 7a). Thus, we tested whether RNF208-mediated
degradation of soluble Vimentin is linked to phosphorylation sites
within the head domain of Vimentin, which is responsible for the
interaction with RNF208. We generated various phosphorylation
site mutants within the head domain of Vimentin. Interestingly,
RNF208 did not bind to the Vimentin (S39A) mutant compared
with wild-type protein and other serine mutants (Fig. 7b; Sup-
plementary Fig. 10). We also investigated the physiological sig-
nificance of the interaction between RNF208 and phosphorylated
Vimentin at the Ser39 residue (S39) with or without MG132.
RNF208 strongly interacted with endogenous phosphorylated
Vimentin (S39) in the presence of MG132 compared to the con-
trol (Fig. 7c). To support this observation, we used a constitutively
active mutant (S39D) of Vimentin. Ectopic expression of RNF208
did not affect the expression levels of the phosphorylation-
incapable Vimentin (S39A) mutant, whereas the constitutively
active Vimentin (S39D) mutant was strongly destabilized by
RNF208 overexpression, similar to that of wild-type protein
(Fig. 7d). Consistent with this result, an immunoprecipitation
assay revealed that RNF208 interacted with wild-type and con-
stitutively active Vimentin (S39D) upon MG123 treatment,
whereas inactive Vimentin (S39A) significantly reduced the
binding capability of RNF208 (Fig. 7e). We also examined whether
the Ser39 residue of Vimentin was required for polyubiquitination
by RNF208. Importantly, RNF208 overexpression induced
polyubiquitination of wild-type as well as active Vimentin (S39D),
whereas polyubiquitination of inactive Vimentin (S39A) was
reduced even in the presence of RNF208 (Fig. 7f). Therefore, these
results suggest that phosphorylation of Vimentin at Ser39 is cri-
tical to facilitate RNF208-mediated polyubiquitination of
Vimentin and attenuation of Vimentin stability. Reportedly,
phosphorylation of Vimentin at Ser39 is induced by AKT, even-
tually promoting cell motility and invasiveness18. Considering that
Vimentin (S39) is increased in TNBC cells compared to luminal
subtype cells (Supplementary Fig. 11a), we further examined
whether RNF208 influences cell migration by targeting phos-
phorylation of Vimentin (S39). Indeed, ectopic expression of wild-
type or active Vimentin (S39D) in MCF-7 nonmetastatic luminal
cells increased cell migration compared to control or inactive
Vimentin (S39A)-overexpressing cells, whereas RNF208 over-
expression resulted in the reduction of cell motility in the presence
of wild-type or active Vimentin (S39D) (Supplementary Fig. 11b,
c). Taken together, our findings suggest that RNF208 specifically
targets phosphorylated Vimentin at Ser39 as a soluble form for
polyubiquitination-mediated degradation, ultimately suppressing
metastasis.
Discussion
In this study, our findings suggest a unique role of the RNF208 E3
ligase as a novel negative regulator of soluble Vimentin, thereby
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inhibiting metastasis of TNBC. In addition to the overexpression
of RNF208 in luminal subtype breast cancers, our results indi-
cated that RNF208 serves as an estrogen-inducible protein that
plays a role in blocking the aggressiveness of breast cancers.
Furthermore, we demonstrated a mechanism by which RNF208
decreased the stability of soluble Vimentin via K27-linked poly-
ubiquitin-mediated proteasomal degradation by recognizing
phosphorylated Vimentin at Ser39, eventually attenuating TNBC
progression (Supplementary Fig. 12).
Considering that ERα is a transcription factor that regulates
gene expression in mammary gland development and that its
dysregulation is closely associated with breast cancer progression,
ERα-dependent target molecules may be associated with aggres-
sive breast cancer progression, and their relationship remains to
be elucidated. In this study, based on gene expression profiles and
immunohistochemistry analyses of breast cancer specimens, we
showed that RNF208 was specifically underexpressed in human
TNBC cells and in primary TNBC tissues compared to luminal
subtype tissues; reduced expression of RNF208 resulted in the
decreased recurrence-free survival of breast cancer patients,
suggesting that aberrant expression of RNF208 was strongly
associated with poor clinical outcomes. Furthermore, public
microarray datasets revealed a significant correlation of RNF208
expression with expression status of ERα in human breast can-
cers. Thus, our findings strongly suggest that RNF208 expression
may be a significant prognostic marker to predict breast cancer
progression, depending on ERα expression status.
Additionally, ERα expression is epigenetically silenced by DNA
methyltransferase or histone deacetylases in the ESR1 promoter of
TNBC cells, leading to an aggressive phenotype and the failure of
endocrine therapy19. Several studies have shown that re-
expression of functional ERα by treatment with DNMT and
HDAC inhibitors resulted in significant growth inhibition in
TNBC cells20,21. Furthermore, although it was recently termi-
nated, a clinical trial aimed at reactivating ERα, which can be
targeted by antiestrogen agents, by a combination of DNMT and
HDAC inhibitors to patients with TNBC has been conducted
(ClinicalTrials.gov, NCT01194908). However, these studies raise
questions about how re-expression of ERα suppresses cancer
progression in TNBC cells. Considering that the lack of RNF208
in patients with TNBC seems to be due to exclusive down-
regulation of ERα, it is feasible that upregulation of RNF208
induced by re-expression of ERα in TNBC cells may act as a
tumor suppressor. Indeed, RNF208 is dependent on ERα re-
expressed by 5-aza-dC in TNBC cells, and its expression was also
upregulated through EREs within the promoter region of RNF208
upon E2 treatment, indicating that RNF208 is a novel estrogen-
inducible target gene in an ERα-dependent manner. Moreover,
overexpression of RNF208 markedly suppressed the tumorigenic
and metastatic capacity of TNBC cells in vitro and in vivo.
Therefore, we expect that the induction of RNF208 via ERα re-
expression by using epigenetic agents may exert anticancer effects
in ERα-negative breast cancers. Additionally, our observations
may provide the mechanistic basis for the identification of
patients who are most likely to benefit from ERα-targeted
therapies. Furthermore, in parallel with ERα studies in hormone
receptor-negative breast cancer therapy, ligand-mediated activa-
tion of ERβ has also shown potent anti-proliferative effects in
TNBC cells through the suppression of metastatic phenotypes22–
24. It is possible that RNF208 expression may be associated with
the expression status of ERβ, similar to ERα. However, because
the molecular classification of breast cancer subtypes is mainly
defined by ERα expression and most of public gene expression
profiles do not fully reflect different profiles between ERα and
ERβ, we could not analyze the correlation between RNF208 and
ERβ expression. Further studies will be required for deeper
insight into the role of RNF208 in ERα/β-dependent or -inde-
pendent pathways during breast cancer progression. Further-
more, considering that PTMs, such as ubiquitination,
sumoylation, phosphorylation, and acetylation, regulate stability
of E3 ligase proteins via cross-talk with other proteins, expression
of RNF208 protein may be regulated by PTMs in a context-
dependent manner. Further studies will be required to better
understand the PTMs of RNF208 in various cancer cells.
Although RNF208 belongs to the RING finger (RNF) protein
family and serves as an E3 ubiquitin ligase, the functional roles of
RNF208 have not been reported. To our knowledge, the findings
presented here are the first to demonstrate an association between
RNF208 and Vimentin in breast cancer progression. Our results
showed that overexpression of RNF208 induced destabilization of
Vimentin through K27-linked polyubiquitin-mediated proteaso-
mal degradation, resulting in a decrease of metastasis in TNBC
cells. Further supporting this observation, mutation analysis of
RNF208 showed that inactivation of the RNF208 E3 ligase failed
to induce degradation of Vimentin and rescued metastasis in
TNBC cells. In the current study, our findings raise questions
regarding how RNF208 regulates the functions of Vimentin
associated with metastasis in TNBC cells. Previous studies have
reported that Vimentin is functionally regulated by PTMs,
especially phosphorylation, eventually contributing to enhanced
tumor growth and metastasis25. In particular, AKT1 phosphor-
ylates Vimentin at Ser39 residue, which leads to disassembly from
the insoluble form (dephosphorylation) to the soluble form
(phosphorylation), and phosphorylated Vimentin enhances cell
migration and invasiveness18. Based on this fact, we speculated
that RNF208 might induce the degradation of phosphorylated
Vimentin, which promotes metastasis. Our results suggested that
RNF208 specifically recognizes phosphorylated Vimentin at the
Ser39 residue to facilitate polyubiquitin-mediated proteasomal
degradation. Indeed, RNF208 induced the degradation of soluble
Vimentin than insoluble Vimentin and specifically bound to
endogenous phosphorylated Vimentin at the S39 residue. More-
over, RNF208 induced the degradation of constitutively phos-
phorylated Vimentin (S39D) and markedly attenuated the cell
migration and invasiveness enhanced by Vimentin (S39D).
Therefore, RNF208 plays a negative role in aggressive breast
cancer progression by destabilizing AKT-mediated phosphoryla-
tion of soluble Vimentin. Additionally, considering that the
activity of the RNF208 E3 ubiquitin ligase may be responsible for
Vimentin polyubiquitination in breast cancers, further compre-
hensive work is needed to understand the functional roles of
RNF208 in other malignant tumors, and novel substrates ubi-
quitinated by RNF208 should be investigated.
In conclusion, our results present a mechanism by which
RNF208, an estrogen-inducible E3 ligase, facilitates K27-linked
polyubiquitin-mediated proteasomal degradation of soluble
Vimentin by targeting phosphorylated Vimentin at Ser39, thereby
exerting a unique function of RNF208 in breast cancer progres-
sion. In addition, given that the ERα expression status is strongly
linked to breast cancer subtypes, RNF208 may be useful as a
prognostic marker in breast cancers, and modulation of RNF208
in an ERα-dependent manner may be a therapeutic intervention
against metastatic breast cancers.
Methods
Cell culture and reagents. The human breast cancer cell lines MCF-7, T47D,
Hs578T, and MDA-MB-231 were obtained from the American Type Culture
Collection (ATCC); ZR-75B, cloned from the ZR-75-1 cell lines26, was obtained
from the National Cancer Institute (NCI)/NIH. The breast cancer cell lines were
cultured at 37 °C in DMEM medium with 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin. Medium and reagents for cell culture were purchased from
WELGENE, Inc., Republic of Korea. In particular, MCF-7 and T47D cells were
cultured in DMEM medium without phenol red with 10% dextran-coated charcoal
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(Sigma)-stripped FBS and 1% penicillin/streptomycin for 24 h prior to 17β-
estradiol treatment. The cell lines in this study were not found in the database of
commonly misidentified cell lines maintained by ICLAC and NCBI Biosample and
were routinely tested for mycoplasma contamination by PCR. Transfections were
carried out using Fugene® HD (Promega) or Lipofectamine® RNAiMAX Reagent
(Invitrogen) according to the manufacturer’s instructions. Cycloheximide (01810),
17β-estradiol (E2758), 5-aza-2′-deoxycytidine (A3656), MG132 (C2211), Bafilo-
mycin A1 (B1793), Chloroquine (C6628), 3-methyladenine (M9281) and N-
ethylmaleimide (E3876) were purchased from Sigma-Aldrich.
Plasmids. Full-length human RNF208 complementary DNA (cDNA) was ampli-
fied from MCF-7 cDNA by PCR and subcloned into the EcoRI and XhoI sites of the
pCS4-3Flag vector or pCMV-Myc vector (Addgene), resulting in Flag-RNF208 and
Myc-RNF208. RNF208 cDNA was subcloned into the ClaI and NotI sites of pEBG-
GST (NIH). Flag-RNF208 or Myc-RNF208 was subcloned into the XhoI and ClaI
sites of the LPCX vector (NIH), resulting in LPCX-Flag-RNF208 or LPCX-Myc-
RNF208, respectively. Human Flag-Vimentin was kindly provided by J.P. (AICT,
Korea), and HA-Ub and HA-Ub mutants (K27/K29/K48/K63) were kindly pro-
vided by S.H.P. (Sungkyunkwan University, Korea). The human RNF208 promoter
was amplified by PCR from the genomic DNA of MCF-7 cells and isolated by a
HiYieldTMGenomic DNA Mini Kit (Real Genomics). The amplified PCR fragment
was cloned into the KpnI and XhoI sites of the pGL3 basic vector (Promega).
Primer sequences for PCR amplification in this study are listed in Supplementary
Data 1.
Generation of stable cell lines. For generation of retroviruses, GP2-293 cells were
plated on a 100-mm culture plate 24 h before transfection. Transfection was per-
formed using polyethylenimine (PEI) with 10 μg DNA and 5 μg VSV-G per plate.
For the knockdown experiment, Lenti-293 cells were seeded in 100-mm culture
plates 24 h before transfection of 10 μg DNA, 10 μg Δ8.2 and 5 μg VSV-G using
PEI. After transfection, the conditioned medium containing recombinant retro-
viruses or lentiviruses was collected and filtered through 0.45-μm sterilization fil-
ters. Then, 3 ml of filtered retroviruses was applied immediately to MDA-MB-231
and Hs578T cells, and 3 ml of filtered lentiviruses was added to T47D cells, which
had been plated for 18 h before infection in a 100-mm culture dish. Polybrene
(Sigma-Aldrich) was added to a final concentration of 8 μg ml−1, and the super-
natants were incubated with the cells for 8 h. The medium was aspirated and
replaced with fresh viral supernatant, and the procedure was repeated. After
infection, the cells were placed in fresh growth medium for 24 h and cultured as
usual. Selection with 2 μg ml−1 puromycin (Sigma-Aldrich) was initiated 48 h after
infection. For transient knockdown of ERα, 20 μM of siESR1 RNA duplex (Bio-
neer) was transfected using Lipofectamine® RNAiMAX Reagent (Invitrogen) in
target cell lines.
RNA extraction, RT-PCR and real-time qRT-PCR. Total RNA was isolated from
cells and tissues using the easy-BLUE Total RNA extraction kit (Promega)
according to the protocol provided by the manufacturer. Reverse transcription was
carried out with 2 μg of purified RNA using M-MLV reverse transcriptase (Pro-
mega, M1705). The synthesized cDNA was amplified by PCR using specific pri-
mers. PCR products were visualized by electrophoresis on 1.5% agarose gels with
Redsafe (Chembio, 21141) staining and analyzed with an ImageQuant LAS 4000
image analyzer (GE Healthcare). The 18S rRNA gene was used as an internal
control. Quantitative real-time PCR (qRT-PCR) was performed with the proper
primers using 2× SYBR Green PCR Master Mix (TaKaRa) and conducted by
QuantStudio 5 (Applied Biosystems).
RNA sequencing. Total RNA was treated with DNase I, purified with the miR-
NAeasy Mini Kit (Qiagen) and subsequently quality checked using an Agilent 2100
Bioanalyzer (Agilent). An Illumina platform (Illumina) was used to analyze tran-
scriptomes with a 90 bp paired-end library. RNA sequencing data have been
deposited in the Gene Expression Omnibus (GEO) database under accession code
GSE100878.
Chromatin immunoprecipitation. ChIP assays using ERα ChIP grade antibody
(Abcam) were performed as described previously27. In particular, the crosslinked
cells were sonicated by a Bioruptor TOS-UCW-310-ES (output, 250W; 21 cycles of
30 s of sonication with 30 s internals; Cosmo Bio, Japan). The primer sequences are
described in Supplemental Data 1. EREs on the RNF208 promoter region were
predicted using PROMO v3.0.2 software. For normalization, 5% of input chro-
matin was used in the PCR analyses.
CRISPR genome editing. To delete −1131/−1124 region of RNF208 promoter, we
generated guide RNA (gRNA) using GeneArtTM Precision gRNA Synthesis Kit
(invitrogen) according to the protocol provided by manufacturer. MCF-7 cells were
transfected with the gRNA, ssODN and Cas9 protein (Toolgen) using the Neon
Transfection System following the manufacturer’s protocol. To generate RNF208
knockout cells, we inserted the annealed target sequence oligo into PX459 vector
(Addgene) following the Zhang lab protocol28. Cells were infected with lentiviral
particles upon 8mgml−1 polybrene treatment. After infection, virus-containing
medium was replaced with normal medium and then RNF208 knockout cells were
re-selected in 2 mgml−1 puromycin. The target sequence and ssODN sequence
informations are listed in Supplementary Data 1.
Human breast cancer tissue microarray and immunohistochemistry. Human
breast cancer tissues from surgical section at the Gangnam Severance Hospital,
Yonsei University College of Medicine (Seoul, Korea) were collected between
January 1996 and December 2004 after approval by the institutional review board
(IRB approval number 3-2013-0268). All procedures involving human participants
were performed in compliance with the relevant ethical standards. For immuno-
histochemistry, each TMA slide was stained with rabbit polyclonal anti-RNF208
antibody (Abcam, ab121658) and counterstained with hematoxylin. After staining,
slides were scored under a microscope and analyzed for RNF208 and Vimentin
expression levels depending on the breast cancer subtype.
In vivo tumor formation and lung metastasis. All procedures were approved by
the CHA Laboratory Animal Research Center (Seongnam, Korea) and Woojung
Bio Animal facility (Suwon, Korea). For the tumor-formation assay, a total of 1 ×
107 retrovirus-infected Hs578T and MDA-MB-231 cells were resuspended in 1:3
PBS/hydrogel (The Well Bioscience) solution and subcutaneously injected into 6-
week-old female NOD/ShiLtJ-Rag2em1AMC Il2rgem1AMC (NRGA, Joong Ah
Bio) mice (n= 6 per group) to measure tumor growth. Tumor size was monitored
weekly starting at 4 weeks after injection, and tumor volume was calculated using
the formula V= (A × B2)/2, where V is volume (mm3), A is the long diameter
(mm), and B is the short diameter (mm). For the lung metastasis assay, retrovirus-
infected MDA-MB-231-Luc cells (1 × 106) were injected into female NOD/SCID
mice through the tail vein. The occurrence of lung metastasis was monitored
weekly starting 4 weeks after injection, and the bioluminescence signals were
measured using an IVS-200 system (Xenogen Corp). Lungs were stained with India
ink, and nodules were counted for quantitative analysis. Tumor tissues were fixed
in 10% formalin solution and embedded in paraffin block. The slide sections were
stained with the indicated antibodies for immunohistochemistry.
Immunoprecipitation and immunoblot analysis. Cells were washed twice in cold
PBS and lysed in IP buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100,
0.5% sodium deoxycholate, 2 mM EDTA and 10% glycerol) plus phosphatase and
protease inhibitors (Roche). Whole-cell extracts were incubated with the appro-
priate primary antibodies overnight at 4 °C. Antibody-bound proteins were pre-
cipitated with Dynabeads (Thermo Fisher Scientific) or Glutathione Sepharose 4B
(GE Healthcare) according to the manufacturer’s protocol. The beads were washed
three times with lysis buffer and then eluted in 2× SDS sample loading buffer.
Eluted proteins were separated by SDS–polyacrylamide gel electrophoresis, trans-
ferred to PVDF membranes (Millipore), and detected using appropriate primary
antibodies coupled with a horseradish peroxidase-conjugated secondary antibody
by chemiluminescence (GE Healthcare). Rabbit antibody against RNF208
(ab175506, dilution 1:1000) and Ubiquitin (linkage-specific K27) (ab181537,
dilution 1:1000) and mouse antibody against Vimentin [V9] (ab8069, dilution
1:1000), Vimentin [RV202] (ab8978, dilution 1:1000) and ERα [E115] (ab32063,
dilution 1:1000) were from Abcam. Mouse antibody against Ubiquitin (sc-8017,
dilution 1:1000), GST [B-14] (sc-138, dilution 1:2000) and Myc [9E10] (sc-40,
dilution 1:2000) and rabbit antibody against p-Vimentin S39 (sc-16673, dilution
1:500) and HA [Y-11] (sc-805, dilution 1:1000) were from Santa Cruz. Mouse
antibody against Flag [M2] (F3165, dilution 1:5000) and β-actin [AC-74] (A5316,
dilution 1:10000) were from Sigma. Mouse antibody against E-cadherin (610181,
dilution 1:1000) was from BD Biosciences and rabbit antibody against Cleaved
Caspase-3 (#9664, dilution 1:1000) was from Cell Signaling. For fractionation of
the soluble/insoluble proteins, cell lysate was lysed using RIPA buffer [20 mM Tris-
HCl (pH 7.5). 150 mM NaCl, 1 mM Na2EDTA. 1 mM EGTA. 1% NP-40] and
dissociate the supernatant and pellet. Insoluble proteins were eluted in 2× SDS
sample loading buffer after boiling for 5 min at 95 °C. The primary antibodies used
are listed in Supplementary Data 2.
Crosslinking for protein interaction analysis. Crosslinking of RNF208-
overexpressing Hs578T cells for mass spectrometry analysis was performed as
described previously29. In particular, cells were fixed in 1% formaldehyde in PBS.
Eluted proteins were loaded on SDS-polyacrylamide gel and separated by elec-
trophoresis. Crosslinked proteins on gel were stained in Coomassie blue (Tech &
Innovation) and analyzed through mass spectrometry at Korea Basic Science
Institute (Daejeon, Korea). The RNF208 binding partner candidates are listed in
Supplementary Data 3.
In vitro ubiquitination assay. Flag-Vimentin, Myc-RNF208, and HA-Ub plasmids
were transfected into 293T cells, and 10 μM MG132 was added 6 h before the cell
harvest. Then, 293T cells were lysed in SDS lysis buffer [10 mM Tris-HCl (pH 8.0),
150 mM NaCl, 1% SDS, 5 mM NEM, protease inhibitor]. The lysates were boiled
for 10 min and were diluted tenfold with dilution buffer [10 mM Tris-HCl (pH
8.0), 150 mM NaCl, 1% Triton X-100]. The protein lysates were rotated with Flag
(Sigma-Aldrich) overnight at 4 °C. Antibody-bound proteins were precipitated
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with Dynabeads (Thermo Fisher Scientific). The precipitates were washed once
with washing buffer A [10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton X-
100, 0.1% SDS] and twice with washing buffer B [10 mM Tris-HCl (pH 8.0), 150
mM NaCl, 1% Triton X-100]. The proteins were eluted in 2× SDS sample loading
buffer and were subjected to Western blot analysis.
Luciferase assay. RNF208 promoter luciferase was transfected into MCF-7 or
T47D cells using FuGENE HD (Promega). The luciferase activities were analyzed
using the Luciferase Assay System Kit (Promega) according to the manufacturer’s
protocol. All assays were performed in triplicate, and the luciferase activities were
normalized against β-galactosidase activities.
Cell migration and invasion assays. Transwell migration assays were performed
using Transparent PET membrane inserts (Falcon, 353097) as described in the
manufacturer’s protocol. A total of 5 × 104 cells were plated in the insert and
incubated for 16 h. Invasion assays were performed with BioCoat Matrigel invasion
chambers (Corning, 354578) as described in the manufacturer’s protocol. Cells
were starved in DMEM medium without FBS for 24 h. Starved cells (1 × 105) were
plated in the top chamber, which contained serum-free DMEM, and the bottom
chamber contained DMEM with 10% FBS. After 24 h of incubation, noninvasive
cells were removed with a cotton swab. The cells that migrated through the
membrane and adhered to the lower surface of the membrane were fixed with 70%
ethanol and stained with 0.05% crystal violet. The numbers of invaded cells in each
field of view were quantified for statistical analysis.
Wound-healing assay. Cells were seeded with 1 × 105 cells in a six-well plate for
18 h in normal culture medium. The p200 tips were applied for cell scraping and
wound creating. After scraping, cells were incubated in low serum medium (1%
FBS contained) for the indicated times. For a comparison of the wound-healing
percentage, 0 h images were taken immediately after wound creation using an
inverted epifluorescence microscope (Nikon Ti-E H600L) with a ×20 objective. The
wound-healing percentage was calculated at the indicated time from the images
taken. The cell migration area was measured between dashed regions by ImageJ
and normalized to control cells.
Statistics and reproducibility. Statistical significance was calculated by using
GraphPad Prism 5 and SPSS version 18 software in this study. The significance of
predicting relapse-free survival in patients with breast cancer was analyzed by using
the log-rank Mantel−Cox test. One-way analysis of variance (ANOVA) was used
to compare different breast cancer subtypes in GDC datasets. For all other com-
parisons, the unpaired two-tailed Student’s t test was used. P < 0.05 was considered
statistically significant. All experiments were repeated at least three times. No
statistical method was used to predetermine sample size. Sample size was chosen
on the basis of literature in the field.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
RNA sequencing data for Fig. 1a have been deposited in the NCBI GEO under accession
code GSE100878. RNA sequencing datasets for Fig. 1d, e were downloaded from the
Genomic Data Common (GDC) data portal (http://portal.gdc.cancer.gov) and deposited
public microarray datasets for Figs. 1c, f, 2a, and Supplementary Fig. 2 are available in
the GEO database under accession codes GSE2034 30, GSE5460 31, GSE41313 32, and
GSE68379 33. Relapse-free survival for Fig. 1i and Supplementary Fig. 1 was analyzed by
the Kaplan−Meier Plotter analysis tool (http://kmplot.com/analysis). The source data for
Figs. 1c, f, h, 2a, c, e, g, 3a, b, e, f, h, and 6g and Supplementary Figs. 3a−c, 5b, 8a, b, 9a, b
and 11c have been provided as Source Data file.
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